In a report released today, Andreas Argyrides from Wedbush reiterated a Hold rating on RegenXBio (RGNX – Research Report), with a price target of $29.00. The company's shares closed last Friday at $27.70. According to TipRanks.com, Argyrides ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.3% and a 30.4% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and BioMarin Pharmaceutical. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $47.71 average price target.
https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-hold-rating-on-regenxbio-rgnx-3?utm_source=advfn.com&utm_medium=referral
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more REGENXBIO Charts.
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more REGENXBIO Charts.